US Stock Insider Trading | Alkermes discloses 6 insider transactions on February 2

K-LinePoet · 2026-02-04T18:47:35+00:00

Alkermes disclosed multiple insider transactions on February 2, 2026, with Director Cooke Shane purchasing 61,200 shares on that day. Additionally, executive Hopkinson Craig C. also engaged in multiple buy and sell transactions, indicating insiders' active trading in the company's stock.

K-LinePoet

2026-02-04 18:47:35

Abstract generation in progress

On February 2, 2026, Alkermes (ALKS) disclosed six insider transactions. Director Shane Cooke purchased 61,200 shares.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 2, 2026	Executive	Craig C. Hopkinson	February 2, 2026	Sell	5,000	34.24	$171,200
February 2, 2026	Director	Shane Cooke	February 2, 2026	Sell	32,100	34.78	$1,116,900
February 2, 2026	Executive	Craig C. Hopkinson	February 2, 2026	Sell	4,000	33.54	$134,200
February 2, 2026	Executive	Craig C. Hopkinson	February 2, 2026	Buy	5,000	19.34	$96,700
February 2, 2026	Director	Shane Cooke	February 2, 2026	Sell	29,100	34.34	$998,800
February 2, 2026	Director	Shane Cooke	February 2, 2026	Buy	61,200	31.64	$1,936,400
January 8, 2026	Executive	Craig C. Hopkinson	January 8, 2026	Buy	5,000	19.34	$96,700
January 8, 2026	Executive	Craig C. Hopkinson	January 8, 2026	Sell	5,000	30.00	$150,000
January 2, 2026	Executive	Craig C. Hopkinson	January 2, 2026	Sell	4,000	28.00	$112,000
December 5, 2025	Executive	Craig C. Hopkinson	December 3, 2025	Buy	3,748	19.34	$72,500

【Company Profile】

Alkermes Public Limited Company was established in Ireland on May 4, 2011, as a private limited company named Antler Science Two Limited (Registration No. 498284). The company is a fully integrated global biopharmaceutical company that leverages scientific expertise and proprietary technology to develop innovative medicines to improve patient outcomes. The company has a diversified product portfolio, including over 20 marketed pharmaceutical products and numerous clinical candidates for treating central nervous system disorders such as addiction, schizophrenia, and depression.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.